Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven locally advanced or metastatic unresectable adenocarcinoma of the biliary tract~* signed written informed consent~* age \> 18~* WHO PS 0 or 1 at study entry~* measurable (diameter ³ 1 cm) / evaluable disease, according to RECIST criteria~* adequate renal (serum creatinin\<1.5x upper reference range), liver (total bilirubin\<2x upper reference range) and hematopoietic functions (PMN\>1,5x109/L, platelets\>100x109/L)~* life expectancy of at least 12 weeks~* effective contraception throughout the study for both male and female patients if the risk of conception exists~Exclusion Criteria:~* uncontrolled concurrent CNS, cardiac, infectious diseases~* previous exposure to epidermal growth factor targeting therapy~* known hypersensitivity to any components of study treatments~* previous chemotherapy for this cancer~* previous malignancy in the last past 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix~* pregnancy or breast feeding~* medical or psychological conditions that would not permit the patient to complete the study or sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): gemcitabine+cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).